The results showed that an anti-EGFR antibody could significantly improve OS (HR = 0.51, 95% CI = 0.39–0.66) and DFS (HR = 0.68, 95% CI = 0.54–0.86) compared to RT or chemoradiotherapy alone, but concurrent anti-EGFR antibody plus radiotherapy failed to achieve survival benefits compared with traditional cytotoxic-drug-based CCRT in locoregionally advanced NPC patients (37). This evidence concerns the gene EGFR and nasopharyngeal carcinoma.